Business
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones
INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales and Inventory Adjusted Net Product Sales of Approximately $240 Million and $258 Million,
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales and Inventory Adjusted Net Product Sales of Approximately $240 Million and $258 Million, Respectively\n INGREZZA® (valbenazine) Preliminary Full-Year 2020 Net Product Sales and TRx Both Grew 32% to Approximately $993 Million and 175,700 TRx Respectively Versus the Prior Year\n Company Plans to Provide Clinical Data for Key Programs and Expects to Initiate Seven Additional Mid-to-Late Stage Clinical Studies in 2021 for Neurological, Endocrine and Psychiatric Disorders\n\n\nSAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product and inventory adjusted sales results of INGREZZA® (valbenazine) for 2020, and key commercial and clinical development milestones for 2021. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, will discuss these updates as part of a webcast presentation at the 39th Annual J.P. Morgan Healthcare Conference to be held virtually on Monday, January 11 at 2:00 p.m. Eastern Time, followed by a Question and Answer session at approximately 2:20 p.m. Eastern Time. \n\n \n \n \n \n \n \n\n \nPreliminary Fourth Quarter and Full-Year 2020 INGREZZA® (valbenazine) Net Product Sales and Inventory Adjusted Net Product Sales (Unaudited)\nBased on preliminary unaudited financial information, the Company expects INGREZZA net product sales for the three months and full-year ended December 31, 2020 to be approximately $240 million and $993 million respectively. Preliminary analysis of INGREZZA net product sales suggests:\n- INGREZZA inventory adjusted net product sales for the fourth quarter were approximately $258 million reflecting an $18 million channel inventory decrease in Q4 \n- New prescriptions and refills increased in the fourth quarter of 2020 vs. the third quarter of 2020\n- Full-year 2020 total INGREZZA prescriptions grew 32% to approximately 175,700 versus 2019 total prescriptions of approximately 132,700 \n\"I am very proud of our team's resilience and adaptability to bring INGREZZA to patients living with tardive dyskinesia this past year and we remain encouraged by the continued strength in persistence and refill rates, which is a testament to the many benefits of INGREZZA. We also continue to focus on healthcare provi...